Disposition of [14C]-LY3023703 Following Oral Administration in Healthy Subjects
Phase of Trial: Phase I
Latest Information Update: 23 Jul 2018
Price : $35 *
At a glance
- Drugs LY 3023703 (Primary)
- Indications Acute pain
- Focus Pharmacokinetics
- Sponsors Eli Lilly
- 29 Jan 2014 Status changed from suspended to discontinued as reported by ClinicalTrials.gov record.
- 21 Nov 2013 Status changed from recruiting to suspended as reported by ClinicalTrials.gov.
- 29 Oct 2013 New trial record